There are reports of failure of extended-spectrum cephalosporin treatment in pneumococcal meningitis. On the basis of in vitro and animal experimental studies, the addition of vancomycin or rifampin to an extendedspectrum cephalosporin has been recommended for empiric treatment of these patients. Cerebrospinal fluid (CSF) was taken from 31 children with bacterial meningitis randomized to receive ceftriaxone alone (n ‫؍‬ 11), ceftriaxone plus rifampin (n ‫؍‬ 10), or ceftriaxone plus vancomycin (n ‫؍‬ 10). The CSF from children receiving ceftriaxone alone was unable to kill intermediately ceftriaxone-resistant or fully resistant strains when the concentration of ceftriaxone in the CSF was less than 5 g/ml. At higher concentrations bactericidal activity was present. We have shown that vancomycin penetrates reliably into the CSF of children with acute meningitis, which is in contrast to previous studies with adults. The addition of vancomycin or rifampin to ceftriaxone resulted in significantly enhanced CSF bactericidal activity compared with that of ceftriaxone alone against these resistant strains. Our data suggest that the addition of rifampin or vancomycin to ceftriaxone may be useful for the treatment of cephalosporin-resistant pneumococcal meningitis.
The extended-spectrum cephalosporins cefotaxime and ceftriaxone are widely used as empiric therapy for acute bacterial meningitis in children (4) .
In 1991, Bradley and Connor (3) described the failure of ceftriaxone therapy to sterilize the cerebrospinal fluid (CSF) of a child infected with a pneumococcus (ceftriaxone MIC of 2 g/ml). A number of subsequent reports (11, 16) have led to a revision in the breakpoint for pneumococcal resistance to cefotaxime and ceftriaxone (12) . Currently the addition of vancomycin or rifampin to a cephalosporin is recommended for treatment of pneumococcal meningitis. These recommendations are based on animal studies and in vitro data (7) .
When rabbits are given doses of extended-spectrum cephalosporins that reach levels in CSF similar to those found in humans, resistant strains are not killed (8) . Both in vitro and in the rabbit meningitis model, the addition of vancomycin results in a synergistic bactericidal effect (7) . Recent data, however, from the rabbit meningitis model suggest that the coadministration of dexamethasone, now widely used for children with meningitis (1), reduces CSF penetration by vancomycin and abolishes the synergistic effect of the combination of ceftriaxone with vancomycin (14) .
The objectives of the present study were (i) to measure the penetration of ceftriaxone, rifampin, and vancomycin into the CSF of children with meningitis who were receiving dexamethasone therapy, (ii) to determine the ability of the children's CSF to kill pneumococci resistant to extended-spectrum cephalosporins, and (iii) to assess the impact of the coadministration of vancomycin or rifampin with ceftriaxone on the killing activity of the CSF.
MATERIALS AND METHODS
Children Յ5 years of age presenting with signs and symptoms of acute bacterial meningitis were entered into the study. Twenty-seven of 31 children enrolled had evidence of infection with Streptococcus pneumoniae, Haemophilus influenzae, or Neisseria meningitidis by culture of CSF. The remaining four patients all had CSF containing Ͼ1,000 neutrophils per mm 3 in the initial or repeat lumbar puncture specimen, increased protein concentrations in CSF, and decreased glucose concentrations in CSF, and all responded to the antimicrobial therapy given. The demographic data and CSF findings are presented in Table 1 .
All children were treated empirically with intravenous ceftriaxone and were randomized on admission into one of three groups. Group 1 (n ϭ 11) received ceftriaxone alone. Group 2 (n ϭ 10) received ceftriaxone plus 60 mg of vancomycin per kg of body weight per day, divided into four doses. Group 3 (n ϭ 10) received ceftriaxone plus rifampin at 20 mg/kg/day given in two doses, orally or via nasogastric tube. Therapy based on randomization was continued until a repeat lumbar puncture was performed 24 to 48 h after admission. The second lumbar puncture was performed 2 to 3 h following the administration of ceftriaxone. In each case the ceftriaxone infusion was given over a few minutes at the end of the vancomycin infusion (over 1 h) or immediately after the dose of rifampin. Serum was obtained simultaneously with the lumbar puncture to compare the levels of antibiotic in serum and CSF. After the repeat lumbar puncture, culture and susceptibility results from the initial lumbar puncture were available, and therapy was modified accordingly. All patients received dexamethasone at 0.6 mg/kg/day, divided into four doses for 4 days, which is in common with therapeutic practice at Baragwanath Hospital at this time.
The first 7 patients enrolled received 50 mg of ceftriaxone per kg twice daily, 6 other patients received 80 mg/kg as a single daily dose, and the remaining 18 patients received 100 mg/kg as a single daily dose. The initial twice-daily dosing was due to a practical consideration at this hospital, where the pediatricians in charge of individual patients were unwilling at the start of the study to use once-daily dosing for fear of the consequences of a missed dose in this busy and often understaffed hospital. After seven patients were enrolled, permission was granted for once-daily dosing for the duration of this study. As data had thus been collected following the administration of 50 mg/kg to 7 patients, it was decided that a dose-ranging component would be included in the study: 6 additional patients (2 in each group) received 80 mg/kg, while the remaining 18 patients (6 in each group) received 100 mg of ceftriaxone per kg.
Assay of CSF bactericidal activity. Three bacterial strains were used. The first (S40) was a fully susceptible pneumococcus (serotype 23F) isolated from a child with bacterial meningitis at Baragwanath Hospital. The second strain (JM) was of intermediate susceptibility to ceftriaxone (CROi), and the third strain (JG) was resistant to the extended-spectrum cephalosporins (CROr) according to the newly introduced breakpoint (12) . Strains JM and JG (both of serotype 6B) have been previously used in the rabbit experimental meningitis model (8) . The MICs were determined with cation-supplemented Mueller Hinton broth with 2.5% lysed horse blood, and the MBCs were read on 5% horse blood agar plates. For the bactericidal assays, organisms were grown for 3 h in serum broth (5% human serum), standardized to a MacFarland standard of 1, and diluted 1:100 with 1/4-strength Ringer's solution to a final concentration of 1 ϫ 10 6 to 5 ϫ 10 6 organisms per ml. CSF (150 l) was added to 150 l of 10% serum in saline and double diluted to provide a range of dilutions of CSF from 1:2 to 1:256. Assays were performed with each of the three bacterial strains; 450 l of CSF was thus used for these assays. As approximately 1 ml of CSF is routinely obtained from lumbar puncture in children at our hospital, no additional volume was required for the assays, but we were precluded by this design of the assay from the measurement of bactericidal activity in neat CSF (requiring an additional 450 l per patient). Ten microliters of the standardized concentration of organisms was added to each well to provide a final concentration of approximately 10 5 organisms per ml. After 2 h of incubation at 37ЊC, 10 l of the solution was removed and plated out on blood agar. An additional 10 l was removed at the same time and diluted 10-, 100-, and 1,000-fold and similarly plated for colony counts. Bactericidal activity was defined as 99.9% kill, and the lower limit of detectability was 100 organisms per ml. The same procedure was performed at 6 h of incubation. Antibiotic carryover was assessed by incorporating a broad-spectrum ␤-lactamase into the plates used for the colony counts and was found not to influence the results at the concentrations of the drugs found in the CSF. Reproducibility of the assays was confirmed directly by repeating the assay on some samples and indirectly by measuring the reproducibility of the bactericidal assay with known concentrations of an antibiotic diluted in 10% serum saline. The mean difference in four experiments with three trials each was 0.13 Ϯ 0.11 log 10 bacterium per ml.
Drug concentrations in CSF. Ceftriaxone was measured by biological assay with Escherichia coli NTCC 10418 by using antibiotic medium 1 (pH 6.6) (2). This E. coli strain is resistant to vancomycin and rifampin, and the concentrations of these drugs found in CSF were shown not to interfere with the assay. Rifampin was assayed, by using Sarcina lutea NTCC 8340, on diagnostic sensitivity test agar (2) after ceftriaxone was neutralized with a broad-spectrum ␤-lactamase (Genzyme Biochemicals Ltd., Kent, England). Vancomycin was assayed with the TDX system (Diagnostics Division, Abbott Laboratories, Abbott Park, Ill.), using a fluorescence polarization immunoassay with competitive binding.
Ethics. The study was approved by the Committee for Research on Human Subjects at the University of the Witwatersrand and included the obtaining of informed consent from the parents or guardians of all children.
Statistics. Statistical analysis was performed by Student's t test or by one-way analysis of variance, using the Newman Keuls multiple-comparisons test.
RESULTS
Demography and CSF characteristics. The ages of the patients, distribution of pathogens, and CSF characteristics are presented in Table 1 . The mean amount of time between the administration of ceftriaxone and the repeat lumbar puncture was 2.8 h. All of the strains isolated were susceptible to ceftriaxone, and the clinical outcomes were similar for the three groups. All repeat CSF specimens were sterile, and there were no significant differences in the changes in CSF characteristics between the initial and repeat lumbar punctures among the three groups.
MICs. The MICs and MBCs of the antibiotics used in the study against the susceptible strain S40, the intermediately cephalosporin-resistant strain CROi, and the fully resistant strain CROr were, respectively, as follows: for ceftriaxone, 0.03 and 0.03, 1.7 and 4, and 4 and 8 g ml Drug concentrations. The ceftriaxone concentrations in CSF and simultaneous levels in blood at a mean of 2.8 h following drug administration were as follows (means Ϯ standard deviations): for 50 mg of ceftriaxone per kg twice daily, 6.6 Ϯ 4.5 and 54 Ϯ 17 g/ml, respectively; for 80 mg of ceftriaxone per kg once daily, 6.7 Ϯ 4.7 and 116 Ϯ 36 g/ml, respectively; and for 100 mg of ceftriaxone per kg once daily, 8.8 Ϯ 8.2 and 93 Ϯ 53.4 g/ml, respectively. Concentrations in serum after administration of 50 mg of ceftriaxone per kg were approximately half of those when 80 to 100 mg/kg was given (P Ͻ 0.01). In contrast, however, we did not find any significant difference in the concentrations in CSF.
The concentrations of drugs in CSF and serum in the three treatment groups are presented in Table 2 . There were no 
Bactericidal activity of the CSF. In the CSF from 10 of the 11 patients receiving only ceftriaxone, and in the CSF from the patients receiving combination therapy, rapid bactericidal activity against the susceptible pneumococcus (S40) was indicated by a reduction in CFU to below the limit of detection (Ͻ100 organisms per ml) within 2 h. The only patient yielding CSF with diminished bactericidal activity at 2 h had the lowest measured concentration of ceftriaxone in CSF (0.9 g/ml). In the CSF from two of the patients receiving only ceftriaxone, colonies of S40 were detectable after 6 h of incubation, whereas in none of the CSF samples from patients receiving combination therapy were any colonies of S40 detectable after 6 h of incubation. The bactericidal activity of ceftriaxone alone against S40 was retained at CSF dilutions of Յ1:8.
The bactericidal activities in CSF of ceftriaxone alone against the CROi and CROr strains are shown in Table 3 . Ceftriaxone alone was poorly active at a 1:2 dilution against both the intermediately and fully resistant strains, with better activity in those patients in whom the ceftriaxone level in CSF exceeded 5 g/ml (Table 3) . Against the intermediately resistant strain, killing was significantly greater at 2 h (P ϭ 0.01) and 6 h (P ϭ 0.006) when the ceftriaxone concentration in CSF was Ͼ5 g/ml (n ϭ 5) than when the concentration in CSF was Ͻ5 g/ml (n ϭ 6). Against the fully resistant strain, a similar reduction in the viable bacterial count of 2 log 10 /ml was obtained when the concentration of ceftriaxone in CSF was Ͼ5 g/ml (compared with Ͻ5 g/ml), but the variance in these two groups was greater and the difference did not reach statistical significance.
The addition of vancomycin increased the killing activity of the CSF against the intermediately resistant strain at both 2 and 6 h, compared with the killing activity with ceftriaxone alone (P Ͻ 0.05) ( Table 3) . This difference was also demonstrated with the fully resistant strain at 2 h (P ϭ 0.05) and 6 h (P Ͻ 0.01) ( Table 3) .
The administration of rifampin similarly enhanced the CSF activity against the cephalosporin-resistant strains. This increased bactericidal activity against both the intermediately and fully resistant strains at both 2 and 6 h was significant. The bactericidal activity illustrated in Table 3 is the activity of the CSF at a dilution of 1:2. No significant bactericidal activity against the resistant organisms could be obtained reliably at CSF dilutions of Ͼ1:2.
Serum bactericidal activity. Excellent bactericidal activity (Ն99.9% reduction in bacterial concentrations) was achieved by serum at a mean of 2.8 h after injection. At a 1:2 dilution after 6 h of incubation, Ն99.9% kill was seen for 27 of 29 serum samples assayed against the CROi strain. For the remaining two isolates, the kills were 96.7 and 90%. A 99.9% kill was obtained for 23 of 29 CROr isolates. For the remaining six isolates at this time interval and serum dilution, growth was inhibited by 99.8, 99.7, 99.7, 99.2, 98.7, and 80%.
DISCUSSION
The assessment of the clinical relevance of pneumococcal resistance to the extended-spectrum cephalosporins is based on anecdotal clinical case reports (3, 11, 16) , data from the experimental rabbit meningitis model (7), and in vitro killing curves (9) . We have designed a method that applies in vitro The first P value is for the ceftriaxone levels at both 2 and 6 h after administration at Ͻ5 g/ml and at Ͼ5 g/ml. Other P values compare combination therapy and ceftriaxone alone.
techniques to clinical CSF specimens in order to measure the antibacterial activity of ceftriaxone therapy alone and in combination with other drugs against ceftriaxone-resistant pneumococci in individual patients.
The ideal experimental approach would be to use CSF from patients infected with ceftriaxone-resistant pneumococci. These cases are rare, and we therefore administered the drugs under investigation to children with any cause of bacterial meningitis and assumed that antibiotic concentrations in CSF were independent of etiology. Our data support this assumption.
When the CSF from our patients was tested in vitro against the CROi and the CROr strains, ceftriaxone alone did not reduce the colony counts of these organisms at the CSF dilution used (1:2). These strains were chosen because they have been used previously in studies of experimental meningitis in rabbits (8, 14) . The MIC of ceftriaxone against CROi was determined to be 1 g/ml in those studies but was 1.7 g/ml in the present study. A possible explanation of this difference is that the media used in the present study were cation supplemented (12) . The MIC for the CROi strain in unsupplemented Mueller-Hinton broth with 5% sheep blood was 1 g/ml (11a). CROi thus represents a strain at the breakpoint between intermediate and full resistance. The concentration of ceftriaxone in CSF varied widely, from 0.9 to 30 g/ml, confirming previous reports (5, 10) . We found a 2-to 3-log reduction in concentrations of the CROi strain when the level of ceftriaxone in CSF was Ͼ5 g/ml. A similar but nonsignificant trend was noted for the fully ceftriaxone-resistant strain. These data provide direct evidence of the inability of CSF, following ceftriaxone administration, to kill resistant pneumococci. They are consistent with the clinical observation that the CSF of patients infected with resistant or intermediately resistant strains may fail to sterilize when treated with ceftriaxone therapy alone (3, 11, 16) . They also explain the observation that some patients respond to cephalosporin therapy (17) . Treatment is more likely to succeed if peak ceftriaxone levels in CSF are higher than 5 g/ml, at least against intermediately resistant strains, although the drug was often bacteriostatic rather than bactericidal at these concentrations. As the CSF killing studies were performed at a dilution of 1:2, it is possible that undiluted CSF may be somewhat more active against these strains.
In vitro (9) and animal experimental data (8) suggest that the addition of vancomycin or rifampin may be of benefit against resistant strains. Conversely, rifampin appeared to be antagonistic to ceftriaxone in a study using a high inoculum (10 7 organisms) and stationary growth culture (6) . We found that the administration of these drugs, in conventional pediatric doses, in combination with ceftriaxone did result in increased bactericidal activity against CROi and CROr strains within 2 h; this activity was sustained at 6 h. Because CSF samples were taken when concentrations of ceftriaxone in CSF were approaching their maximum (3 to 4 h after infusion), the in vitro studies reflect the optimal killing kinetics of the therapeutic regimens. There is concern that the administration of dexamethasone may compromise CSF penetration by various drugs (14) . The ceftriaxone levels we obtained were similar to those previously reported for patients with meningitis in the absence (5) and presence (10) of dexamethasone and are higher than those achieved with patients with uninflamed meninges (13) . This is the first report of vancomycin concentrations in CSF in children with acute bacterial (non-shunt-related) meningitis. The administration of vancomycin for the treatment of meningitis in adults has been frustrated by unpredictable CSF penetration and a wide range of achieved levels of the drug in CSF. Low levels in CSF correlated with poor clinical outcome (18) . Our data suggest that vancomycin in a dosage of 60 mg/kg/day penetrates reliably into the CSF of young children with acute meningitis and that the range of drug concentrations in CSF achieved in this population is predictable. As no children received vancomycin or rifampin alone, i.e., without ceftriaxone, the bactericidal activity of these agents against the CROi and CROr strains was not measured directly. A 1:2 dilution of 10% serum saline containing the mean level of vancomycin in CSF found in this study (3.3 g/ml) or 1 g of rifampin per ml did not, however, reduce the colony counts of these strains at 2 or 6 h of incubation (11a). Although these data do not exclude significant bactericidal activity of these agents in neat CSF, they do support the idea that the bactericidal activity found at a 1:2 dilution of CSF in this study was due to a synergistic combination of ceftriaxone with these agents.
In experimental meningitis, a successful outcome correlates with a peak CSF antibiotic concentration 10 times greater than the MBC for the infecting organism (15) . None of the agents we tested achieved concentrations in CSF that were 10 times greater than the MBC for CROi and CROr pneumococci. The killing of CROi or CROr pneumococci by CSF would require concentrations of ceftriaxone (or cefotaxime) in the range of 40 to 80 g/ml, a vancomycin concentration of 5 to 10 g/ml, and a rifampin concentration of 1.2 to 2.5 g/ml. Our data therefore suggest that the combination of these agents may be a clinically rational intervention. We should caution, though, that the bactericidal activity of the combinations at a 1:2 dilution of CSF was not maintained at a 1:8 dilution and that the bactericidal activity of ceftriaxone against the susceptible strain could not be reached with the CROi and CROr strains even with combination therapy. Our data also therefore support the investigation of new agents which may have enhanced bactericidal activity against these strains. The use of methods similar to ours will allow the in vitro assessment of activity against other rare human pathogens. This type of assay has particular relevance for clinical situations in which new patterns of bacterial resistance are associated with clinical failure.
In contrast to CSF activity, the serum activity against these resistant pneumococci was excellent, as may be expected by the very high drug levels measured in blood. Concentrations in blood were not peak levels in serum (samples of which are usually taken 30 to 60 min after an intravenous dose), but despite this, all 31 specimens had very high bactericidal activity measured after 6 h of incubation with the CROi strain. Similarly, the activity against the CROr strain of serum at a 1:2 dilution at the time of the collection of CSF was excellent, with only six specimens having any detectable bacterial growth (80 to 99.8% killing) at 6 h of incubation. These data suggest that cephalosporin resistance in pneumococci is not at present clinically relevant for the treatment of pneumococcal bacteremia with ceftriaxone and similar agents.
